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Introduction Patients with heart failure (HF) and reduced ejection fraction (HFREF) are at 
increased risk of death and hospitalizations for HF. Numerous registries have reported a large and 
persistent gap between real-life practice in the use of life-saving evidence-based therapies (such 
as renin angiotensin system inhibitors, beta blockers, mineralocorticoid receptor antagonists 
(MRA) and recommended practices in international guidelines. The fear of inducing hyperkalemia  
and or worsening renal function are the main triggers of this underuse. 
 
The problem: epidemiology and lack of use of effective therapeutics 
The MRA spironolactone and eplerenone have been shown to reduce cardiovascular death and 
hospitalizations for heart failure as well as total mortality and total hospitalizations in patients with 
chronic heart failure and HFREF. On this basis they have received a class 1 indication in major 
European and US guidelines 1. In contrast to other class 1 recommendations for patients with 
chronic HFREF such as beta adrenergic receptor antagonists and angiotensin converting enzyme 
inhibitors (ACE-I) or angiotensin receptor blockers (ARB) the use of MRA remains suboptimal 
both in Europe and the US 1. In large part, this under use of MRA in guideline eligible patients 
with chronic HFREF appears to be due to a fear of inducing serious hyperkalemia and or worsening 
renal function . Although spironolactone was associated with a 30% reduction in cardiovascular 
mortality as well as a significant reduction in hospitalizations for heart failure in patients with 
severe chronic HFREF (Randomized Aldactone Evaluation Study (RALES)) a report by Juurlink 
et al 2  in the New England Journal of Medicine from Canada soon after the publication of the 
results of the RALES study pointed out that the use of  spironolactone in patients with chronic 
HFREF was associated with an increase in hospitalization for hyperkalemia. A critical review of 
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the study shows however that many patients in this study used a dose higher than the dose of 
spironolactone recommended in the RALES study (12.5-50 mg/day) ; had worse renal function 
than patients included in the RALES study ; and most importantly in contrast to patients in RALES 
many patients from Canada had a baseline serum potassium ( K+ ) > 5.0 mmol/l and or did not 
undergo serial monitoring of K+ and renal function. Furthermore, Juurlink’s findings were not 
replicated in a longitudinal analysis of the UK National Health Service in Scotland. In this study, 
an increase in mild hyperkalemia was reported after the publication of RALES, but it did not 
translate into increased hospitalizations or death due to hyperkalemia. The authors attributed the 
finding to more rigorous monitoring practices 3. Given the risk of sudden cardiac death associated 
with the development of  hyperkalemia  (K+ > 5.0 mmol/l )4 as well as the increased costs 
associated with the need for hospitalization of patients with hyperkalemia it is understandable that 
clinicians  trained  to “ do no harm“  have tended to avoid initiating MRA in guideline eligible 
patients with chronic HFREF. However while the fear of inducing hyperkalemia is reasonable in 
patients at increased risk for its development such as those with an estimated glomerular filtration 
rate (eGFR)  < 45 ml/min /1.73m2 and or a K+ > 4.8 mmol/l, MRA are also  avoided in  patients 
with chronic HFREF at a relatively low risk for developing serious hyperkalemia ( K+ ≥ 6.0 
mmol/l),  thereby denying these patients proven  life and cost saving  therapy. In a consecutive 
series of 500 patients hospitalized with a diagnosis of acute decompensated HF only 21% of 
eligible patients for a MRA on admission received them. Of interest was the finding that 
preadmission and newly started MRA were discontinued in 36% of patients during the period of 
hospitalization, with worsening renal function being the most common identifiable reason. After 
a medium follow-up of 57 days, an additional 6% of patients discontinued their MRA 5.  
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Management of patients when hyperkalemia and or worsening renal function interferes with 
successful use of MRA added to a background of renin angiotensin system blockade. 
Recent data have however cast some doubt as to the risks associated with an increase in K+ to > 
5.0-5.5 mmol/l as well as the risks associated with worsening renal function. While the risk of 
serious hyperkalemia (K+ ≥  6.0 mmol/l) is well documented recent data from the Eplerenone in 
Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF have 
suggested that the development of mild-moderate hyperkalemia ( > 5.0-5.5 mmol/l may not be 
significantly  associated with an increased risk of death  with a MRA6 and that the development of 
hypokalemia (K+< 4.0-3.5  mmol/l ) may be a far greater risk for death in patients with chronic 
HFREF7. Importantly in this trial, as per protocol , the  patients serum potassium was monitored 
after 1 week, 1 month, and every 4 months thereafter. Patients with an elevation of serum 
potassium ≥ 5.5 mmol/l could decrease study drug or discontinue it in case of hyperkalemia ≥6 
mmol/l. The study drug could however be reintroduced if the serum potassium measured within 
72 hours, was < 5.0 mmol/l.  Serum creatinine was monitored at baseline, month 5, then every 8 
months. If there was an unplanned interruption in the administration of study drug/eplerenone for 
any period of time, the subject may resume study drug/eplerenone as directed by the investigator. 
The dosage resumed was at the discretion of the investigator (not to exceed 50 mg once daily for 
subjects with an eGFR ≥ 50 ml/min/1.73m2 and 25 mg once daily with an eGFR between 30-49 
ml/min/1.73m2). The dynamic management of eplerenone 6  may have contributed to maintenance 
of study drug throughout the trial as well as to its efficacy and safety. Such an algorithm may 
provide guidance for the daily management of  MRA in clinical practice. Of note, the European 
Society of Cardiology guidelines for heart failure management includes tables with practical 
guidance on the use of ACEi/ARB or MRA in patients with HFREF (web tables 7.4 and 7.6)8. 
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While there is evidence that mild –moderate hyperkalemia can be associated with an increased risk 
of death, the risk associated with any given level of K+ depends upon the rate of change in K+,   
intracellular  potassium and magnesium levels, serum calcium +  level,  and pH.  The approach to 
and the treatment of patients with chronic hyperkalemia is undergoing change. Until recently 
patients with chronic hyperkalemia  have  been  recommend to  be on a  low potassium diet; to 
eliminate  potassium supplements  and drugs that compromise renal function such as non-steroidal 
anti-inflammatory drugs ; to initiate treatment with  a non-potassium sparring diuretic if indicated  
or if already on a diuretic to  increase the dose ; as well as to reduce the dose or discontinue RAAS-
I, especially MRA.  However, reducing the dose of the RAAS-I or discontinuing it could place the 
HFREF patient at increased risk for death.    In this situation one might consider the use of a 
potassium lowering agent while continuing a RAAS-I9. Interestingly,  the recent availability in the 
US of the well tolerated and effective potassium lowering agent patiromer which exchanges 
potassium for calcium  allows  a reduction of K+ to normokalemic values and may open new 
therapeutic avenues for hyperkalemic HFREF patients on optimal RAASI regimen 9.   
A recently published metaanalysis of randomized placebo controlled trials of renin angiotensin 
aldosterone system inhibitors (RAAS)-I) in chronic HF shows that in HFREF, worsening renal 
function induced by RAAS-I therapy was associated with a less increased relative risk of mortality 
(Relative Risk (RR) 1.19(1.08-1.31), p<0.001), compared with worsening renal function induced 
by placebo (RR 1.48(1.35-1.62), p<0.001)(p for interaction 0.005)10. The reason for an increase in 
serum creatinine after initiation of a RAAS-I, especially a MRA, is well understood and is 
associated with a decrease in vascular tone. There is no evidence that this decrease in renal vascular 
tone is detrimental and associated with adverse renal structural changes since RAAS-I withdrawal 
is associated with a return in serum creatinine toward normal. On the contrary evidence suggests 
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that RAAS-I, including   MRA, have a beneficial effect on renal function and structure. They 
reduce mesangial and glomerular fibrosis, apoptosis, podocyte loss, and have been shown to have 
a beneficial effect on cardiovascular and renal outcomes, at least for ACE-I and ARB. Thus, the 
accumulating evidence would suggest that patients with chronic HFREF who are initiated on a 
RAAS-I be allowed to continue therapy if they develop worsening renal function (i.e. an increase 
in serum creatinine > 30%). However, if the worsening renal function is associated with serious 
hyperkalemia (K+ > 6.0 mmol/l) and or new ECG changes suggestive of hyperkalemia; or 
symptoms associated with the development of renal failure that the RAAS-I be temporarily 
discontinued and  appropriate therapy for  hyperkalemia (i.e. a potassium binder), if indicated, be 
initiated. This may be followed by a re-initiation of RAAS-I after down-titration. This strategy 
would allow a greater percentage of patients with chronic HFREF to remain on RAAS-I, especially 
MRA thereby potentially preventing cardiovascular death, hospitalizations for heart failure, and 
increased health care costs. Further prospective adequately powered randomized clinical trials as 
well as further analysis of “real life” observational databases or registries will be essential to 
inform clinical guidelines and practice. In the interim clinicians will need to weigh the risks and 
benefits of discontinuing RAAS-I, especially MRA, in patients with chronic HFREF who develop 
mild-moderate hyperkalemia and or worsening renal function on an individual basis. While it may 
be easier to withdraw a RAAS-I than to continue it in these circumstances the accumulating 
evidence suggests that in many instances   the decision to continue the use of a RAAS-I will in the 
long run results in a favorable effect on renal structure, function and cardiovascular outcomes.   
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